Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Tixagevimab/cilgavimab  COVID-19 treatment studies for Tixagev../c..  C19 studies: Tixagev../c..  Tixagev../c..   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Melatonin (meta)
Aspirin (meta) Metformin (meta)
Bamlaniv../e.. (meta) Molnupiravir (meta)
Bebtelovimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Cannabidiol (meta) Nitric Oxide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)
Lactoferrin (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 30% Improvement Relative Risk Recovery 7% primary c19early.com/tc Holland et al. NCT04501978 ACTIV-3-TICO Tixagev../c.. RCT LATE Favors tixagevimab/ci.. Favors control
Holland, 1,417 patient tixagevimab/cilgavimab late treatment RCT: 30% lower mortality [p=0.03] and 7% improved recovery [p=0.21] https://c19p.org/holland
copied to clipboard
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial
Holland et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(22)00215-6, ACTIV-3-TICO, NCT04501978 (history)
8 Jul 2022    Source   PDF   Share   Tweet
RCT with 710 hospitalized patients treated with tixagevimab/cilgavimab, and 707 placebo patients, showing lower mortality with treatment.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2 [Zhou].
risk of death, 30.0% lower, RR 0.70, p = 0.03, treatment 61 of 710 (8.6%), control 86 of 707 (12.2%), NNT 28, day 90.
risk of no recovery, 7.4% lower, RR 0.93, p = 0.21, treatment 710, control 707, sustained recovery, day 90, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Holland et al., 7/8/2022, Double Blind Randomized Controlled Trial, placebo-controlled, USA, peer-reviewed, 103 authors, study period 10 February, 2021 - 30 September, 2021, trial NCT04501978 (history) (ACTIV-3-TICO).
Contact: adit.ginde@cuanschutz.edu.
All Studies   Meta Analysis
This PaperTixagev../c..All
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit